Lenvatinib bulk supplier for pharma manufacturers

Lenvatinib 4 mg , 10 mg Suppliers & Bulk Manufacturers

Available Forms: Oral capsules

Available Strengths: 4 mg , 10 mg

Reference Brands: Lenvima® (EU & US)

Lenvatinib (brand name Lenvima®) is an oral tyrosine kinase inhibitor used to treat thyroid cancer, RCC, HCC, and endometrial cancer. Available in 4 mg and 10 mg capsules, it’s approved in the US and EU. Widely sourced by B2B pharma suppliers, Lenvatinib ensures GMP-compliant, reliable supply for oncology centers with competitive pricing.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Lenvatinib, marketed as Lenvima® by Eisai, is a potent oral tyrosine kinase inhibitor (TKI) used in oncology to treat thyroid cancer, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and endometrial carcinoma. Available in 4 mg and 10 mg capsules, Lenvatinib is approved in both the US and EU. It works by inhibiting tumor angiogenesis and cell proliferation. As a high-demand anticancer therapy, it is widely distributed by pharma B2B suppliers across the European and U.S. markets, ensuring GMP-compliant sourcing, consistent availability, and competitive pricing for hospitals, pharmacies, and oncology centers managing advanced cancers.

Lenvatinib — third party manufacturing & bulk supply

Lenvatinib 4 mg , 10 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Lenvatinib is supplied as Oral capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Lenvatinib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Lenvatinib →

Back to Listing

Frequently Asked Questions

Lenvatinib is listed as Oral capsules in 4 mg , 10 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Lenvatinib is referenced against Lenvima® (EU & US). Reference brands are shown for identification only and remain the property of their respective trademark owners.